Free Trial
→ Your book is inside (From Profits Run) (Ad)tc pixel Free STX Stock Alerts

Shield Therapeutics (STX) Competitors

Shield Therapeutics logo
GBX 5.91 -0.24 (-3.90%)
As of 05/29/2026 12:13 PM Eastern
Compare

STX vs. ELX, TAO, APC, DGI, and IDEA

Should you buy Shield Therapeutics stock or one of its competitors? MarketBeat compares Shield Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Shield Therapeutics include El Oro (ELX), TAO Alpha (TAO), Apc Technology Group (APC), DG Innovate (DGI), and Ideagen (IDEA). These companies are all part of the "computer hardware" industry.

How does Shield Therapeutics compare to El Oro?

Shield Therapeutics (LON:STX) and El Oro (LON:ELX) are both small-cap computer hardware companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

El Oro has lower revenue, but higher earnings than Shield Therapeutics. Shield Therapeutics is trading at a lower price-to-earnings ratio than El Oro, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Shield Therapeutics£49.70M1.27-£36.28M-£2.00N/A
El Oro-£7.25M0.00N/A-£2.50N/A

Shield Therapeutics presently has a consensus price target of GBX 15, suggesting a potential upside of 153.81%. Given Shield Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Shield Therapeutics is more favorable than El Oro.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Shield Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
El Oro
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

El Oro has a net margin of 0.00% compared to Shield Therapeutics' net margin of -34.53%. Shield Therapeutics' return on equity of 103.62% beat El Oro's return on equity.

Company Net Margins Return on Equity Return on Assets
Shield Therapeutics-34.53% 103.62% -47.85%
El Oro N/A N/A N/A

1.1% of Shield Therapeutics shares are held by institutional investors. 3.0% of Shield Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Shield Therapeutics' average media sentiment score of 0.00 equaled El Oro'saverage media sentiment score.

Company Overall Sentiment
Shield Therapeutics Neutral
El Oro Neutral

Summary

Shield Therapeutics beats El Oro on 9 of the 11 factors compared between the two stocks.

How does Shield Therapeutics compare to TAO Alpha?

Shield Therapeutics (LON:STX) and TAO Alpha (LON:TAO) are both small-cap computer hardware companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

In the previous week, Shield Therapeutics' average media sentiment score of 0.00 equaled TAO Alpha'saverage media sentiment score.

Company Overall Sentiment
Shield Therapeutics Neutral
TAO Alpha Neutral

1.1% of Shield Therapeutics shares are owned by institutional investors. Comparatively, 0.7% of TAO Alpha shares are owned by institutional investors. 3.0% of Shield Therapeutics shares are owned by company insiders. Comparatively, 98.3% of TAO Alpha shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Shield Therapeutics presently has a consensus price target of GBX 15, suggesting a potential upside of 153.81%. Given Shield Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Shield Therapeutics is more favorable than TAO Alpha.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Shield Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
TAO Alpha
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

TAO Alpha has lower revenue, but higher earnings than Shield Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Shield Therapeutics£49.70M1.27-£36.28M-£2.00N/A
TAO AlphaN/AN/A-£1.57MN/AN/A

TAO Alpha has a net margin of 0.00% compared to Shield Therapeutics' net margin of -34.53%. Shield Therapeutics' return on equity of 103.62% beat TAO Alpha's return on equity.

Company Net Margins Return on Equity Return on Assets
Shield Therapeutics-34.53% 103.62% -47.85%
TAO Alpha N/A -128.73%-64.09%

Summary

Shield Therapeutics beats TAO Alpha on 8 of the 11 factors compared between the two stocks.

How does Shield Therapeutics compare to Apc Technology Group?

Apc Technology Group (LON:APC) and Shield Therapeutics (LON:STX) are both small-cap computer hardware companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Apc Technology Group's average media sentiment score of 0.00 equaled Shield Therapeutics'average media sentiment score.

Company Overall Sentiment
Apc Technology Group Neutral
Shield Therapeutics Neutral

Shield Therapeutics has a consensus price target of GBX 15, indicating a potential upside of 153.81%. Given Shield Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Shield Therapeutics is more favorable than Apc Technology Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Apc Technology Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Shield Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

1.1% of Shield Therapeutics shares are owned by institutional investors. 3.0% of Shield Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Apc Technology Group has a net margin of 0.00% compared to Shield Therapeutics' net margin of -34.53%. Shield Therapeutics' return on equity of 103.62% beat Apc Technology Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Apc Technology GroupN/A N/A N/A
Shield Therapeutics -34.53%103.62%-47.85%

Apc Technology Group has higher earnings, but lower revenue than Shield Therapeutics. Shield Therapeutics is trading at a lower price-to-earnings ratio than Apc Technology Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apc Technology Group£19.20M0.00N/A£0.50N/A
Shield Therapeutics£49.70M1.27-£36.28M-£2.00N/A

Summary

Shield Therapeutics beats Apc Technology Group on 7 of the 11 factors compared between the two stocks.

How does Shield Therapeutics compare to DG Innovate?

DG Innovate (LON:DGI) and Shield Therapeutics (LON:STX) are both small-cap computer hardware companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

DG Innovate has higher earnings, but lower revenue than Shield Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DG Innovate£24.50K0.00-£4.91MN/AN/A
Shield Therapeutics£49.70M1.27-£36.28M-£2.00N/A

Shield Therapeutics has a consensus target price of GBX 15, indicating a potential upside of 153.81%. Given Shield Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Shield Therapeutics is more favorable than DG Innovate.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DG Innovate
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Shield Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, DG Innovate's average media sentiment score of 0.00 equaled Shield Therapeutics'average media sentiment score.

Company Overall Sentiment
DG Innovate Neutral
Shield Therapeutics Neutral

DG Innovate has a beta of 3.55, meaning that its stock price is 255% more volatile than the broader market. Comparatively, Shield Therapeutics has a beta of 1.877, meaning that its stock price is 88% more volatile than the broader market.

DG Innovate has a net margin of 0.00% compared to Shield Therapeutics' net margin of -34.53%. Shield Therapeutics' return on equity of 103.62% beat DG Innovate's return on equity.

Company Net Margins Return on Equity Return on Assets
DG InnovateN/A -129.16% -50.26%
Shield Therapeutics -34.53%103.62%-47.85%

8.0% of DG Innovate shares are owned by institutional investors. Comparatively, 1.1% of Shield Therapeutics shares are owned by institutional investors. 45.7% of DG Innovate shares are owned by insiders. Comparatively, 3.0% of Shield Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

DG Innovate and Shield Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Shield Therapeutics compare to Ideagen?

Ideagen (LON:IDEA) and Shield Therapeutics (LON:STX) are both small-cap computer hardware companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

Ideagen has a net margin of 0.00% compared to Shield Therapeutics' net margin of -34.53%. Shield Therapeutics' return on equity of 103.62% beat Ideagen's return on equity.

Company Net Margins Return on Equity Return on Assets
IdeagenN/A N/A N/A
Shield Therapeutics -34.53%103.62%-47.85%

Ideagen has higher revenue and earnings than Shield Therapeutics. Shield Therapeutics is trading at a lower price-to-earnings ratio than Ideagen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ideagen£75.28M0.00N/A£0.02N/A
Shield Therapeutics£49.70M1.27-£36.28M-£2.00N/A

1.1% of Shield Therapeutics shares are held by institutional investors. 3.0% of Shield Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Ideagen's average media sentiment score of 0.00 equaled Shield Therapeutics'average media sentiment score.

Company Overall Sentiment
Ideagen Neutral
Shield Therapeutics Neutral

Shield Therapeutics has a consensus target price of GBX 15, suggesting a potential upside of 153.81%. Given Shield Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Shield Therapeutics is more favorable than Ideagen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ideagen
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Shield Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Shield Therapeutics beats Ideagen on 6 of the 11 factors compared between the two stocks.

Get Shield Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for STX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

STX vs. The Competition

Export
MetricShield TherapeuticsDrug Manufacturers IndustryMedical SectorLON Exchange
Market Cap£63.14M£2.21B£5.82B£2.83B
Dividend YieldN/A2.95%2.69%6.07%
P/E Ratio-2.965.1421.63365.74
Price / Sales1.271,759.51590.9687,759.94
Price / Cash6.3610.1843.2227.89
Price / Book108.0010.5610.557.79
Net Income-£36.28M£20.70B£3.56B£5.89B
7 Day Performance-6.78%0.86%2.85%0.82%
1 Month Performance-32.46%5.01%4.59%10.96%
1 Year Performance144.42%20.94%37.62%78.69%

Shield Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
STX
Shield Therapeutics
1.42 of 5 stars		GBX 5.91
-3.9%		GBX 15
+153.8%		+144.4%£63.14M£49.70MN/A40,000
ELX
El Oro
N/AN/AN/AN/A£41.06M-£7.25MN/A1,122
TAO
TAO Alpha
N/AGBX 7.10
+31.5%		N/A+1,190.9%£26.89MN/AN/A3
APC
Apc Technology Group
N/AN/AN/AN/A£18.03M£19.20M19.75164,000
DGI
DG Innovate
N/AN/AN/AN/A£1.90M£24.50KN/A790

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:STX) was last updated on 5/31/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
Read now. Do not delete. You’ve been warned.
Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...
Porter & Company | Sponsoredtc pixel